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Introduction
Acute promyelocytic leukaemia (APL) is a subtype of acute 
myeloid leukaemia (AML), categorised as AML subtype M3, and is 
characterised by translocation of the genes between the long (q) 
legs of chromosomes 15 and 17 [described as t(15;17)(q24;q21)]. 
There are two different classification systems for AML, namely the 
World Health Organization (WHO) and the French-American-British 
(FAB) classifications. The FAB classification divides AML into eight 
subtypes based on morphology and the cytochemical staining 
of blasts.1 The WHO classification is more complicated, since it 
requires evaluation of the blast cells by molecular analysis and flow 
cytometry.1 Classification of the different types of AML is valuable to 
doctors when deciding on which chemotherapy regimen to use after 
remission has been achieved since each type may react differently 
to treatment owing to its different genetic make-up.2 APL usually has 
a good prognosis.3,4
The aetiology of AML M3 or APL includes a genetic predisposition 
to instability in the genes located on the long legs of chromosomes 
15 and 17.3 The genes translocate due to DNA breakage, most likely 
caused by exposure to X-rays, smoking and chemicals, e.g. benzene 
and aromatic organic solvents.5 Obese persons and children with 
Down’s syndrome have an increased risk of developing leukaemia.5,6
The first symptoms of AML are very vague and generalised. 
These include fatigue, malaise, irritability, fever, pallor, weight 
loss, shortness of breath, loss of appetite, anaemia, easy bruising, 
petechiae, purpura, haemorrhage, palpitations, bone and joint pain, 
frequent infections, epistaxis, headaches, and nausea and vomiting, 
as well as mouth ulcers.5,7
Leukaemia is diagnosed via a bone marrow biopsy which is then 
sent for genetic testing (karyotyping) and viewing under a light 
microscope. The blood tests commonly show an elevated white 
blood cell count and reduced platelet count (leukopaenia). Elevated 
levels of lymphocytes (CD13, CD33 and CD117) are demonstrated 
using flow cytometry.3
The main goal of nutritional management in leukaemia patients 
is to maintain lean body mass and protein stores, and to support 
the immune system, which enables the patient to cope better with 
treatment and ensures the best outcome possible for the patient.7
Case study
The patient, a 26-year old unmarried man, was admitted to Port 
Elizabeth Provincial Hospital, Port Elizabeth, on 29 April 2013 
via transfer from the Nelson Mandela Academic Hospital with an 
unconfirmed diagnosis of APL, i.e. AML subtype M3. 
Medical history 
The patient did not have any children and was a non-smoker, with a 
history of alcohol abuse (he had stopped drinking four years earlier). 
Two of his siblings could be tested in the event that a stem cell 
transplant was indicated, since they shared the same two parents 
as the patient. The patient had been unwell since March 2013 with 
fatigue, epistaxis and weight loss (~ 10% over the past six months). 
He also had a history of previous pulmonary tuberculosis six years 
prior, for which he had completed six months of treatment. The 
patient did not present with night sweats, but complained of loss of 
appetite, loss of weight and bleeding gums. 
He had a subacute abdomen with abdominal pain and chronic 
diarrhoea, with no abdominal distension, but with suspicion of 
abdominal perforation, necessitating the initiation of total parenteral 
nutrition (TPN). An abdominal exploration revealed two perforations 
in the caecum secondary to ulceration and Candida albicans 
overgrowth. The terminal ileum was resected and a hemicolectomy 
with anastomoses was performed, necessitating continuation of the 
TPN postoperatively. The patient started passing stools on day 4 post 
surgery (day 9 post admission).
Nutritional assessment
The usual markers were considered during nutritional assessment, 
i.e. anthropometry, biochemistry, clinical signs, diet history and 
medication.
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Anthropometry
The patient weighed 35 kg on admission with a body mass index 
(BMI) of 13.4 kg/m2. The reported usual body weight for the patient 
was ~ 50 kg (BMI of 19.5 kg/m2). 
Biochemistry
On admission, the patient presented with a classic APL picture of 
elevated white cell counts and a reduced counts of red blood cells 
and platelets. He presented with an international normalised ratio 
(INR) of 14, and had thrombi in his right ileac vein. 
The patient showed elevated CD13, CD33 and CD45 white blood 
cell counts, suggestive of APL. On stained slides, Auer rods were 
seen in some cells, i.e. another indication of APL. Fluorescent in situ 
hybridisation, a genetic test commonly referred to as FISH, confirmed 
the diagnosis as APL, due to the genetic translocation seen between 
the 15th and 17th chromosome, i.e. t(15;17)(q24;q21). 
As indicated in Table I a and b, the patient presented with 
refeeding syndrome (hypokalaemia and hypomagnesaemia) after 
the initiation of TPN. Thereafter, he presented with hyperkalaemia 
and hyperphosphatemia, possibly due to oversupplementation 
of intravenous potassium phosphate, indicating the need for 
electrolyte-free TPN. His potassium did normalise for a few days, 
but thereafter he consistently presented with hypokalaemia, even 
with daily intravenous (IV) supplementation with potassium chloride.
The patient’s magnesium levels remained within an acceptable 
range due to magnesium sulphate supplementation IV, since the TPN 
did not contain magnesium. His liver enzymes started to rise by day 
13 of TPN, but he had started to pass stools and it was decided to 
gradually introduce nasogastric tube (NGT) feeding and wean him 
off TPN.
Clinical signs
The patient presented with a right iliac deep vein thrombosis and 
a Serratia urinary tract infection. He also had bilateral pleural 
effusions. He was dehydrated and complained of backache and 
fatigue. Clubbing was not present. He had bleeding gums, secondary 
to a low platelet count and elevated INR, but no gingival hyperplasia, 
a distinguishing factor from acute lymphoblastic leukaemia. He 
also presented with anorexia and history of weight loss. The doctor 
classified him as “severely wasted”. His bone marrow biopsy site on 
his right hip was septic with a Serratia infection, and he had bleeding 
around the anus. 
After surgery, the patient developed abdominal fluid collection, 
wound dehiscence and neutropaenic sepsis with concomitant 
infections of vancomycin-resistant enterococci and Klebsiella 
pneumoniae. He was confined to an isolation room for the remainder 
of his stay. Reverse barrier nursing measures were put in place. 
Diet history
The patient was initially kept nil per os for the first two weeks 
because of a small bowel perforation and the resulting surgery. TPN 









Sodium 136-145 mmol/l 140 145 131 146 141 139 146 143 141 141 144 146
Potassium 3.5-5.1 mmol/l 3.8 3.9 3.4 5.9 3.5 3.5 3.4 3.8 3.9 3.9 2.4 2.5 2.6
Chloride 98-107 mmol/l 102 102 97 107 105 107 108 108 105 104 102 99
Urea 2.1-7.1 mmol/l 2.4 3.4 4.4 5.9 6.1 5.9 4.4 6.0 6.1 3.7 5.1 7.3
Creatinine 64-104 umol/l 39 34 56 38 26 15 30 25 29 31 34 38
Conjugated bilirubin 0-3 umol/l 1 3 4 3
Total bilirubin 5-21 umol/l 10 9 16 9 10 9
Total protein 60-78 g/l 58 46 40 42 51 65
Albumin 35-52 g/l 18 17 14 19 16 12 13 16 28
ALP 40-120 U/l 125 150 119 147 211 212 361
GGT 0-60 U/l 86 62 54 96 71 212
ALT 5-40 U/l 34 10 26 13 31 14
AST 5-40 U/l 55 13 71 17 23 14
LDH 266-500 U/l 624
Corrected Ca 2.15-2.55 mmol/l 2.46 2.44 2.34 2.00 2.50 2.40 2.47 2.30 2.66 2.44
Magnesium 0.63-1.05 mmol/l 0.61 0.62 0.83 0.78 0.61 0.78 1.04 0.89 0.69
Phosphate 0.78-1.42 mmol/l 0.87 1.24 1.18 1.76 0.97 1.13 0.95 0.62 0.97 0.37
CRP 0-5 mg/l 37 104 207 121 135 134 185 123 76 100 196 301
ALP: alkaline phosphatase, ALT: alanine transaminase, AST: aspartate transaminase, ATRA: all-trans retinoic acid, Ca: calcium, CRP: C-reactive protein, D: daunorubicin,  
GGT: gamma-glutamyl transferase, L: laparotomy, LDH: lactate dehydrogenase, TPN: total parenteral nutrition
* Total parenteral nutrition extends across days 1-13
** All-trans retinoic acid extends across days 1-23
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was indicated and initiated in consultation with the doctor. Only the 
first TPN bag contained electrolytes. 
The patient was gradually weaned off TPN two weeks after admission 
while NGT feeds were introduced. He eventually progressed to a soft 
neutropaenic ward diet with oral supplementary sip feeds.
Chemotherapy regimens
The translocated gene in APL normally codes for the retinoic acid 
receptor α. Treatment with all-trans retinoic acid (ATRA) induces 
differentiation in the majority of a patient’s cells, which leads to a 
cure.2,8 
The first goal in treating AML with chemotherapy is to achieve 
complete remission by reducing the number of leukemic cells to an 
undetectable level, i.e. < 5% blasts on bone marrow biopsy. There 
are three stages of chemotherapy, namely induction (one six-week 
cycle), consolidation (three cycles) and maintenance (two years). 
The average AML patient receives induction chemotherapy called 
3+7, which consists of a cytosine arabinoside antimetabolite, e.g. 
etoposide or cytarabine; and an anthracycline, e.g. daunorubicin, 
idarubucin or doxorubicin.9 The cytosine arabinoside antimetabolite 
is given for seven days and the anthracycline for three days, thus 
the name, 3+7. A patient with APL also receives an antracycline, in 
addition to ATRA, for six weeks. APL is very sensitive to anthracycline. 
Excellent results have been obtained with this protocol.9 The 
complete remission rate for APL is roughly 95% after induction.10 
It is important to note that all patients in remission will relapse if 
they default on their consolidation or maintenance chemotherapy 
regimens. 
The post-remission or consolidation goal is to eliminate any residual 
undetectable disease and to achieve a cure. There are three cycles of 
consolidation chemotherapy. The first cycle thereof takes place at the 
same time as the induction. Two more consolidation chemotherapy 
cycles follow thereafter. The types of consolidation chemotherapy 
regimens differ between APL and other AML subtypes, and are 
also dependent on other factors, e.g. the patient’s risk (high versus 
standard) and stock levels in the public sector. The patient’s first 
cycle in the haematology unit consisted of adriamycin 25 mg/m2 per 
day for four days. The second cycle was mitoxanthrone 10 mg/m2 
per day for five days, and the third cycle consisted of adriamycin 
60 mg/m2 for one day.
If a patient is still in remission after completing the consolidation 
cycles, he or she receives two years of maintenance chemotherapy 
with methotrexate and 6-mercaptopurine.9,10 Relapsed APL patients 
receive arsenic trioxide instead.4 A prophylactic dose of 50 mg 
cytarabine, 15 mg methotrexate and 30 mg hydrocortisone is 
recommended via intrathecal administration in high-risk patients.11
If APL is suspected in a patient, it is recommended that ATRA 
should be started as soon as possible while waiting for diagnosis 
confirmation9 since it rapidly ameliorates the coagulopathy typically 
seen in APL.4,9 Because ATRA is so successful in inducing molecular 
remission, stem cell transplantation is not usually necessary in APL 
patients.4,10
The patient was placed on the modified Programa para el Tratamiento 
de Hemopatias Malignas (PEMETHA) chemotherapy induction 
protocol, one of the regimens for the treatment of APL, consisting 
Table I b: The patient’s biochemistry and chemotherapy history for the first three weeks of treatment post admission (days 14-23)
Biochemical markers Days Baseline 
(day 0)
14 15 16 17 18 19 21 22 23
Normal range
Sodium 136-145 mmol/l 140 151 149 150 149 143 147 147 145 150
Potassium 3.5-5.1 mmol/l 3.8 2.4 2.4 2.6 2.5 5.7 2.5 3.0 2.6 2.7
Chloride 98-107 mmol/l 102 109 110 113 113 109 107 113 111 114
Urea 2.1-7.1 mmol/l 2.4 16.8 7.2 7.2 6.5 3.7 5.6 5.9 6.6 6.8
Creatinine 64-104 umol/l 39 69 39 37 42 24 50 51 57 66
Conjugated bilirubin 0-3 umol/l 1 6 6 1 12 14
Total bilirubin 5-21 umol/l 10 13 10 28 21 20 21
Total protein 60-78 g/l 58 48 47 60 62 56 56
Albumin 35-52 g/l 18 23 15 14 15 27 15 22
ALP 40-120 U/l 125 358 305 252 424 352 281 293
GGT 0-60 U/l 86 281 196 135 203 157 123 112
ALT 5-40 U/l 34 12 10 9 10 12 7 9
AST 5-40 U/l 55 12 11 8 53 17 10 11
LDH 266-500 U/l
Corrected Ca 2.15-2.55 mmol/l 2.46 2.25 2.16 2.28 2.40 2.25 2.36 2.17 2.12
Magnesium 0.63-1.05 mmol/l 0.61 1.12 0.71 0.74 0.90 0.90 0.77 0.79 0.78
Phosphate 0.78-1.42 mmol/l 0.87 0.57 1.54 1.51 1.50 1.00 0.86 1.01 1.07
CRP 0-5 mg/l 37 199 198 233 210 229 213 166 173.9 166
ALP: alkaline phosphatase, ALT: alanine transaminase, AST: aspartate transaminase, ATRA: all-trans retinoic acid, Ca: calcium, CRP: C-reactive protein, D: daunorubicin,  
GGT: gamma-glutamyl transferase, L: laparotomy, LDH: lactate dehydrogenase, TPN: total parenteral nutrition
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of an anthracycline, e.g. idarubicin, daunorubicin or doxorubicin, and 
ATRA (12 mg/m2 daunorubicin IV bolus on days 2, 4, 6 and 8; and 
45 mg/m2 ATRA daily in two divided oral doses, starting on day 1).11 
The patient’s dose was calculated according to his body surface 
area. The daunorubicin was stopped on day 5 post admission owing 
to surgery for the perforated caecum. Daunorubicin infusion was not 
reinitiated post surgery, but the patient continued on the ATRA daily 
doses until he finished the six-week cycle. 
Other medication
The patient was on antiemetic medication to relieve the nausea 
and vomiting induced by chemotherapy. He also had diarrhoea 
(> 3 loose stools per day) due to antibiotics and IV magnesium 
sulphate administration, and this was managed with paracetamol 
codeine phosphate, a side effect of which is constipation [500 mg 
paracetamol and 20 mg codeine phosphate (two tablets) taken six 
hourly, as needed]. 
Nutritional requirements and care plan
Setting nutrition-related goals in consultation with the patient 
empowered and enabled him to play an active role in his treatment 
and recovery.7
Many patients have nutritional deficiencies even before their 
diagnosis and subsequent treatment. The risk of malnutrition is 
compounded further when treatment is initiated. A micronutrient 
deficiency is possible in most cancer patients who consume 
< 60% of their daily energy requirements for > 10 days. Vomiting 
and diarrhoea further contribute to the loss of micronutrients. 
Adequate nutrition intervention and care can be beneficial to a 
patient’s condition and disease progression.12
The patient’s requirements were calculated according to the 
guidelines set out in Table II. The detailed nutrition care plan is set 
out in Tables III and IV a and b. Requirements were calculated on his 
actual body weight of 35 kg, which amounted to an energy range 
of 1 050-1 225 kcal total energy (30-35 kcal/kg) and 52.5-70.0 g 
protein (1.5-2.0 g/kg) which converted to 8.4-11.2 g nitrogen (N
2) 
(~ 210-280 kcal), with a non-protein energy (NPE) to N2 ratio of 75:1 
to 100:1 (840-1 120 kcal: 8.4-11.2 g N2). Fluid requirements were 
estimated at between 1 050ml (1 ml/kcal or 30ml/kg) and 1 400 ml 
(40 ml/kg).
The patient was initially kept nil per os for two weeks because of a 
small bowel perforation and the resulting surgery. TPN was indicated 
and initiated on admission in consultation with the doctor. He was 
also at risk of developing refeeding syndrome. Therefore, TPN was 
initiated at 20 kcal/kg for the first 24 hours, as recommended by 
Webster-Gandy et al,14 i.e. 700 kcal of total energy and 7 g N2. 
Refeeding syndrome occurs from the introduction of carbohydrates 
into the gastrointestinal tract, which then stimulates insulin 
secretion.15 Insulin then stimulates the sodium-potassium ATPase 
pump. This pump requires magnesium as a co-factor.15 The pump 
drives potassium into the cells and sodium moves out. Insulin 
Table II: Guidelines when assessing the nutritional needs of an adult 
cancer patient13
Nutritional needs estimation Clinical situation
Energy needs
25-30 kcal/kg Maintenance
30-35 kcal/kg* Malnourished and/or high-stress 
treatment, such as a bone marrow 
transplant*
35-45 kcal/kg Severely depleted or 
hypermetabolic
Protein needs
0.8-1.0 g/kg Recommended dietary allowance 
for adults
1.0-1.5 g/kg Most patients with cancer (adjust 
for visceral protein status and 
albumin levels)
1.5 g/kg Bone marrow transplant recipients
1.5-2.0 g/kg* Severely depleted patients with 
cancer*
Fluid needs (choose from one of two of the following methods)
RDA or calorie based 1 ml/kcal
Age-based* < 55 years of age = 30-40 ml/kg*
55-65 years of age = 30 ml/kg
> 65 years of age = 25 ml/kg
RDA: recommended dietary allowance
* Guidelines indicated were used in the case study patient
Table III: A history of total parenteral nutrition administration as per the calculated requirements (1 050 - 1 125 total kcal, 840-1 120 kcal non-protein energy 
and 8.4-11.2 g nitrogen)
Weight used = 35 kg Day 1 TPN Day 2 TPN Day 4 TPN Day 10 TPN
Energy (kcal/kg) 20 32 ml/hour 25 40 ml/hour 30 48 ml/hour 35 56 ml/hour
Total energy (kcal) 700 777 875 980 1 050 1 176 1 225 1 371
NPE (kcal) 640 640 800 800 960 960 1 120 1 120
N2 (g) 6.4 4 8 8.2 9.6 9.8 11.2 11.4
Total protein (g) 40 25 50 51.25 60 61.25 70 71.25
Protein (g/kg) 1.14 0.71 1.43 1.46 1.71 1.75 2 2.0
Total glutamine (g) 
(0.35 g/kg IV)
12.25 3.6 7.3 8.8 10.2
Total fluid (ml) (30 ml/kg) 1 050 768 960 ~ 1 150 1 345
IV: intravenous, N2: nitrogen, NPE: non-protein energy, TPN: total parenteral nutrition
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also stimulates phosphate shifts into the cell.15 Therefore, this 
mechanism leads to low extracellular phosphate, magnesium and 
potassium. Thiamine is an essential co-enzyme for carbohydrate 
metabolism. Thiamine deficiency can develop in a depleted patient 
with refeeding syndrome.15 Therefore, the administration of 250 mg of 
thiamine intravenously was suggested to the doctor according to the 
refeeding guidelines, and 100 mg thiamine weekly thereafter.15 On 
Day 1, we could not use the most suitable all-in-one TPN bag which 
would have provided ~ 640 kcal NPE, 6.5 g N
2 and 5.8 g glutamine owing 
to stock challenges, but instead used a bag containing 640 kcal NPE, 
4 g N
2 and 3.6 g glutamine. A bag with glutamine was chosen 
because of the patient’s risk of chemotherapy-induced mucositis.12 IV 
rehydration was also suggested to ensure that the fluid requirements 
were met; also necessary for medication administration. As a 
result of multiple electrolyte imbalances, including hyperkalaemia 
and hyperhosphataemia (Table I a), the TPN was changed to an 
electrolyte-free bag. The administration rate was increased to 
25 kcal/kg per day on day 2, and 30 kcal/kg on day 4. The patient 
achieved the full rate of 35 kcal/kg by day 10. 
He started passing stools on day 9 and was cautiously monitored 
for a few days. He was weaned off TPN on day 13, while a semi-
elemental NGT feed containing 1 000 kcal and 40 g protein per litre 
(Table IV a) was concurrently introduced. He was off TPN on day 15 
and on full NGT feeds. He started eating orally on day 16, and was 
completely weaned off NGT feeds by day 22 (Table IV b). He was 
then supplemented orally with high-energy, high-protein sip feeds 
to amend his oral intake of the full neutropaenic ward diet. Two sip 
feeds per day provided 800 kcal and 40 g protein.
A 1 mg vitamin B
12 injection was recommended at every follow-up via 
the outpatient clinic because of the patient’s terminal ileum resection. 
The recommended maintenance dosage was 1 mg intramuscularly 
every month, but 6-8 injections a year would suffice.5
The patient was discharged after six weeks of induction and 
consolidation chemotherapy, and was provided with 24 x high-
protein, high-energy sip feeds, providing 400 kcal and 20 g protein 
each; as well as 30 sachets of enriched peanut butter, providing 
500 kcal and 12.3 g protein per sachet. The patient returned in 
two weeks for his second cycle of consolidation chemotherapy, and 
was in morphological remission on day 58. The complete history of 
outpatient supplementation and weight gain is set out in Table V.
Micronutrients
The mechanism of chemotherapy partly depends on the effect 
of reactive oxygen species. The supplementation of antioxidant 
micronutrients may influence this, possibly worsening the patient’s 
Table IV a: A history of dietary progression from total parenetral nutrition to nasogastric tube feeds (days 13-15)
Nutritional requirements Day 13 Day 14 Day 15
TPN wean NGT* feeds Total TPN wean NGT* feeds Total Full NGT feeds*
Administration rate ml/hour 42 21 63 21 42 63 63
Total energy (kcal)   
(35 kcal/kg)
1 225 1 035 500 1 535 517.5 1 000 1 517.5 1 500
NPE (kcal) 1 120 845 487.2 1 332.2 422.5 974.4 1 396.9 1 461.6
N2 (g) 11.2 8.6 3.2 11.8 4.3 6.4 10.7 9.6
Total protein (g) 70 53.75 20 73.75 26.875 40 66.875 60
Protein (g/kg) 2 2.12 1.9
Fluid (ml) (30 ml/kg) 1050 ~ 1 000 ~ 500 ~ 1 500 ~500 ~1 000 ~1500 ~1 500
N2: nitrogen, NGT: nasogastric tube, NPE: non-protein energy, TPN: total parenteral nutrition
* semi-elemental
Table IV b: A history of dietary progression from total parenteral nutrition to nasogastric tube feeds, and later, oral feeds (days 16-22)
Nutritional requirements
NGT feeds*


















Administration rate ml/hour 42 42 21
Total energy (kcal) 
(35 kcal/kg)
1 225 1 000 900 1 900 1 000 900 1 900 500 1 350 1 850 800 900 1 700
NPE (kcal) 1 120 975.68 877.6 1 
853.28
975.68 877.6 1 
853.28
487.84 1 316.4 1 
804.24
774.4 877.6 1 652
N2 (g) 11.2 6.08 5.6 11.68 6.08 5.6 11.68 3.04 8.4 11.44 6.4 5.6 12
Total protein (g) 70 38 35 73 38 35 73 19 52.5 71.5 40 35 75
Portein g/kg 2 2.1 2.1 2.0 2.1
Fluid (ml) (30ml/kg) 1050 ~ 1 000 ~ 1 000 ~ 500
N2: nitrogen, NGT: nasogastric tube, NPE: non-protein energy, TPN: total parenteral nutrition
* standard
** standard with fibre
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prognosis.12 The American Institute for Cancer Research evaluated 
available data on the effect of micronutrient supplementation on 
chemotherapy and radiotherapy. They concluded that taking dietary 
supplements during treatment is safe as long as the amount of 
micronutrients does not exceed the daily recommended dietary 
allowance.12 The intake of antioxidants should not exceed the daily 
upper limits of safe intake, i.e. vitamin C ≤ 2 000 mg/day, vitamin 
E ≤  250 mg alpha-tocopherol equivalent/day, selenium ≤ 400 ug/
day. A daily intake of 500-2 000 mg vitamin C, 3 mg vitamin A, 10-
15 mg vitamin B6, 0.4-1.0 mg folic acid, 4-10 mg zinc and 1-2 mg 
copper is recommended for wound healing post surgery. Tentative 
daily administration of 1.5-2.0 g long-chain omega-3 fatty acids is 
recommended for cancer cachexia and weight loss.12 The patient 
received the following micronutrients daily: 5 mg folic acid, 50 mg 
zinc picolinate containing 9.5 mg elemental zinc, and a vitamin B 
complex twice daily (each tablet contained 5 mg vitamin B1, 2 mg 
vitamin B2, 20 mg vitamin B3 and 2 mg vitamin B6.)
Glutamine
Glutamine forms 25% of the free amino acid pool in the extracellular 
fluid and 60% in the skeletal muscle.16 Skeletal muscle tissue is also 
the main site for L-glutamine synthesis and storage.17 Glutamine 
is released with muscle protein metabolism during infection, 
inflammation or muscle trauma.17 Approximately 30 g of lean tissue 
is broken down for each gram of nitrogen lost during stress, thereby 
releasing alanine and glutamine.18 Glutamine is depleted during any 
damage to the enteric mucosa.19 The pathogenesis of mucositis is 
complex. Both chemotherapy and radiotherapy damage the rapidly 
dividing normal cells, including the mucosal cells, which leads to the 
side-effects of mucositis and bone marrow suppression.20
Conflicting results have been reported in glutamine studies performed 
on oncology. Glutamine increased cell growth17,20 in in vitro studies, 
but tumour growth was reduced in in vivo studies.17 In one of these 
studies, glutamine caused tumour regression as a result of immune 
clearance of the tumour because the glutamine was used as fuel by 
the natural killer cells.20,21 Glutamine was also avidly consumed by 
the tumour cells, while natural killer cells’ activity was depressed 
owing to a decrease in glutathione concentration.17 Although 
glutamine could possibly “feed the tumour”, it was suggested by 
Gaurav et al17 that “because glutamine consumption by tumours 
is almost absolutely dissipative”, increased tumour growth rate 
should be unexpected. Studies show that tumour growth diminishes 
during oral glutamine supplementation by restoring the function 
of the natural killer cells and improving protein metabolism.17 It is 
also possible that oral glutamine supplementation may increase 
the selectivity of anti-tumour drugs owing to increased glutathione 
synthesis, thereby protecting the patient from oxidative stress.17 
Glutamine was also shown to protect against radiotherapy-induced 
oxidative stress.17 The parenteral supplementation of glutamine was 
favoured in many studies in order to bypass erratic bioavailability 
and variable compliance with oral administration, especially in 
patients with feeding difficulties.16
IV glutamine protects the liver cells from oxidative injury by 
increasing intracellular glutathione during chemotherapy. It is also 
been suggested that oral glutamine supplementation enhances 
anti-tumour drug selectivity, protects the normal tissue and 
possibly sensitises the tumour cells to injury both via radiotherapy 
and chemotherapy.17 There is a possible trend in the objective 
reduction of mucositis in non-bone marrow transplant patients 
receiving chemotherapy and/or radiotherapy.20 A lower incidence of 
complications relating to infection resulted in acute nonlymphocytic 
leukaemia patients receiving supplemental glutamine.18
Mucosal breakdown in the gastrointestinal tract can be prevented 
by enteral or parenteral glutamine administration.19 There is some 
evidence that IV glutamine has trophic effects in the ileum and 
proximal and distal colon, which becomes important with potential 
mucosal atrophy during TPN.17 Twenty-five per cent of the control 
group experienced diarrhoea for >10 days, while none of the patients 
Table V:  Weight history of the patient during the first 18 months of treatment
Day Date Weight BMI (kg/m2) Notes 
- 26 April 2013 34.6 kg 13.4 Height of 160.7 cm
1 30 April 2013 35.0 kg 13.4 Started on induction chemotherapy for six weeks
42 10 June 2013 35.0 kg Tolerating a full neutropaenic diet. Six weeks of chemotherapy completed. 
Discharged on INP of 24 x high-protein, high-energy sip feeds and 30 x 
enriched peanut butter sachets
58 26 June 2013 37.9 kg Three quarters of the induction completed. Eating well. No diarrhoea. 
Morphological remission
  26 August 2013 45.2 kg INP: 30 x enriched peanut butter sachets, and 30 x high-energy powder 
sachets (580 kcal, 12g protein). Underwent molecular remission
  9 September 2013 46.2 kg Consolidation #3 INP of 42 x high-energy powder sachets. Doctor’s notes 
report “eating well”
  9 October 2013 46.3 kg Consolidation completed. Started two years of maintenance chemotherapy. 
Doctor’s notes report “slowly gaining weight”
  3 December 2013 49.0 kg 18.6 Height of 162.5 cm (still in remission)
  7 January 2014 to 27 October 2014 49.5-50.6 kg The patient’s weight was maintained on supplements. He was handed over to 
Frere Hospital for further maintenance management on 27 October 2014
BMI: body mass index, INP: Integrated Nutrition Programme
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receiving glutamine experienced diarrhoea in a study conducted on 
AML patients.18
IV glutamine supplementation reduced mucositis in the majority of 
cancer patients receiving chemotherapy.18 Although other modalities 
for mucositis prevention are available, e.g. cryotherapy, granulocyte 
colony-stimulating factor, laser and granulocyte-macrophage 
colony-stimulating factor, efficacy is not uniform.17
High-dose doxorubicin (an anthracycline) causes acute, and 
sometimes chronic, cardiac toxicity.17 Oxidative damage caused 
by doxorubicin decreases glutathione, and depletes superoxide 
dismutase in the cardiac muscle.17 Glutamine plays a protective role 
by upregulating glutathione and inducing heat shock protein, which 
protects the myocardium against hypoxic or ischaemic injury.17 
Glutamine supplementation also maintains cardiac glutathione levels 
during the administration of methotrexate and cyclophosphamide.17
Significantly faster neutrophil recovery was reported in acute 
leukaemia patients on high-dose cytarabine who also received 
20 g IV glutamine as part of parenteral nutrition, possibly as a 
result of the simulation of lymphocyte proliferation.17 Patients on IV 
glutamine supplementation in both of the studies by Piccirillo et al16 
achieved a lymphocyte count > 500 mg significantly faster (p-values 
< 0.001 and 0.009) than patients receiving a placebo.
A reduction in the duration of neutropenia in AML patients was also 
shown with TPN supplemented with glutamine.18 Patients receiving 
glutamine on days 1-5 in a study conducted by Sornsuvit et al18 on 
AML patients receiving chemotherapy lost significantly less weight, 
and had a shorter length of stay and less severe oral mucositis than 
the controls. Webster-Gandy et al14 also support parenteral glutamine 
supplementation because of its association with a shorter hospital 
stay. is cost-effective, because it maintains the nutritional status 
and enhances neutrophil phagocytosis, was provided in the study 
by Sornsuvit et al.18
There are no known drug interactions with glutamine.17 However, 
glutamine is antagonised physiologically by lactulose during the 
treatment of high ammonia levels during liver failure. Glutamate, a 
by-product of the glutamine metabolism, may cause brain excitation 
in patients. The drug may be less effective in patients with seizures.17 
It is contraindicated in cases of renal and hepatic insufficiency and 
metabolic acidosis.
The Mucositis Study Group of the Multinational Association of 
Supportive Care in Cancer and International Society of Oral Oncology 
(MASCC/ISOO)22 has set out evidence-based clinical practice 
guidelines for mucositis. The guidelines, published by the European 
Society for Medical Oncology and the USA National Comprehensive 
Cancer Network, are both adaptations of the MASCC/ISOO guidelines. 
The latest guidelines update, based on systematic reviews of 
evidence for various interventions, was published in May 2014.22 
However, owing to inadequate or conflicting evidence, a guideline 
was not possible in relation to glutamine for all cancers, except in 
haematopoietic stem cell transplantation, where the recommendation 
was against the IV use of glutamine for the prevention of mucositis, 
based on level II evidence.22
A neutropaenic diet
Neutropaenia in chemotherapy patients is a major risk factor for 
infection.23 The rationale behind a neutropaenic diet is that bacterial 
translocation can take place from the gut to other body sites causing 
infection through the ingestion of organisms, such as Pseudomonas 
aeruginosa, Escherichia coli, Aspergillus and Klebsiella spp.23 These 
organisms have been isolated from food, e.g. fresh vegetables, fresh 
salad, raw eggs and cold meat, as well as water and ice.23 Some 
studies have been conducted on the benefit of the neutropaenic 
diet, but the sample sizes were very small.23 Even though the 
literature is inconclusive as to the necessity of a neutropaenic 
diet in neutropaenic patients, and because it was stated following 
a Cochrane Collaboration review that recommendations could not 
be given since no evidence of effect was found, it was decided to 
err on the side of caution in the haematology unit, and place all of 
the oncology patients on a neutropaenic diet. It is prescribed that 
patients follow a neutropaenic diet at home for another six months 
after discharge, as recommended by Webster-Gandy et al.14 There 
are no official published neutropaenic diet guidelines, but basic 
food safety principles are prudent in neutropaenic patients, such 
as avoiding uncooked meat, seafood, eggs, unwashed fruit and 
vegetables,23 as well as hand washing and practising personal 
hygiene.24 The dietary restriction also encompasses yoghurt and 
amasi (sour milk) because of their probiotic content. There is a need 
for larger randomised studies to be conducted on the effectiveness 
of the neutropaenic diet. 
It should be kept in mind that diet alone does not play a role in 
the management of neutropaenia. Antimicrobial prophylaxis, colony-
stimulating factors, a protective environment (i.e. isolation), oral 
care, central venous catheter care, hand washing and personal 
hygiene are recommended for cancer patients on chemotherapy in 
evidence-based guidelines developed by the Centers for Disease 
Control and Prevention for the management of neutropaenia and the 
prevention of opportunistic infections.24
Conclusion
The weight trend shows that the patient managed to maintain his 
weight at 35 kg after six weeks of treatment and nutritional support. 
He was placed on the Integrated Nutrition Program on discharge, 
and managed to gain weight following frequent follow-ups and 
continuous supplementation. The patient was in clinical remission 
(normal neutrophil and platelet counts and < 5% blasts in the bone 
morrow) two-and-a-half months after the initiation of treatment. 
He remained in remission two months later. He received the three 
consolidation chemotherapy cycles. Six months after induction, he had 
completed his consolidation chemotherapy, remained in remission, 
and was placed on two years of maintenance chemotherapy of 
methotrexate and 6-mercaptopurine. He completed his maintenance 
chemotherapy in October 2015 and was deemed cured.
It is important to take note that weight loss in obese patients is 
just as detrimental as weight loss in patients with normal weight 
since even a small amount of weight loss can mask a higher loss of 
skeletal muscle mass.25 
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A long-term multidisciplinary approach to the management of 
oncology patients is recommended. By encouraging the patient, and 
frequently assessing and promptly intervening where nutritional-
related barriers are noticed, the multi-disciplinary team will facilitate 
the patient in reaching his defined nutritional-related goals.7 
Improved physical exercise in haematological cancer patients can 
increase the efficacy of protein intake through stimulating protein 
anabolism after intensive chemotherapy.26 Deterioration in dietary 
intake, sometimes observed in first-stage induction chemotherapy, 
may be attenuated in later chemotherapy cycles or after remission. 
This approach is in line with the recommendation of Malihi et al26 
that the “assessment of patients in further cycles seems of utmost 
importance”, including dietary counselling and supplementation, 
even for outpatients.
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